Scientific Advisory Board
Lyle Ostrow, MD, PhD
ALS Clinician-Scientist at Johns Hopkins
As Chair of the DOD ALS Research Programmatic Panel, he led recent efforts to develop and refine funding mechanisms to help novel treatments move though the drug development pipeline, prioritize biomarker development, and encourage open data and resource sharing. He also Directs the JHU ALS Postmortem Tissue Core, a collaboration with the CDC National ALS Registry which integrates clinical, pathological, and genomic data with autopsy tissue samples and slides – all made broadly available to researchers around the world.
Amir Lahav, ScD
Strategic consultant and a leading innovator in digital health
Amir Lahav is a Digital Health Innovation Advisor and a leading innovator at the forefront of neurological diseases. Amir has nearly two decades of experience in the biotech and healthcare industries. He currently sits on the Advisory Board of leading HealthTech startups, and holds several consulting roles with pharma companies, including Head of Strategic R&D and Digital Health Innovation at Mitsubishi Tanabe Pharma, and Chief of Digital Health Strategy at Redenlab. Formerly, Amir served as the Head of Digital Innovation for Rare Diseases at Pfizer, and prior to pharma, was a PI on numerous clinical trials as a Neurology Faculty and Professor of Pediatrics and at Harvard Medical School.